Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19
Abstract:
The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and/or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.
Public/Granted literature
Information query
Patent Agency Ranking
0/0